Orthofix has demonstrated positive net sales growth and strong performance in U.S. Orthopedics and BGT divisions, alongside successful product launches and strategic initiatives. However, challenges such as pricing pressures in the Spine Fixation segment, international Orthopedics decline, and tariff exposures present ongoing concerns.

Company Guidance

During Orthofix's Second Quarter 2025 Earnings Call, the company provided comprehensive financial guidance and updates on its strategic initiatives. Orthofix reported pro forma net sales of $200.7 million for the second quarter, reflecting a year-over-year constant currency growth of 4%. The USA Spinal Fixation net sales grew by 5.4%, with a procedure volume increase of 7%. The company also highlighted the successful market launch of the TrueLok Elevate Transverse Bone Transport System, contributing to a 28% growth in USA Orthopedics. Additionally, Orthofix announced FDA clearance and the limited market release of the VIRATA Spinal Fixation System, which is designed to integrate with the 7D FLASH navigation system. The 7D unit placements in the U.S. grew by 66% in the first half of 2025, representing a total revenue commitment of approximately $12 million over the life of the contracts. For the full year, Orthofix expects pro forma net sales between $808 million and $816 million and anticipates achieving positive free cash flow, excluding restructuring charges related to discontinued product lines. The company remains focused on driving growth through strategic distributor transitions, product innovation, and enhanced commercial execution.

Pro Forma Net Sales Growth

Orthofix reported second quarter pro forma net sales of $200.7 million, representing a year-over-year constant currency growth of 4%.

USA Spinal Fixation Growth

USA Spinal Fixation net sales grew 5.4%, with procedure volume increasing by 7%.

Strong U.S. Orthopedics Growth

U.S. Orthopedics grew 28% due to the launch of the TrueLok Elevate Transverse Bone Transport System. This marks the fourth consecutive quarter of double-digit U.S. Orthopedics growth.

7D FLASH Navigation System Adoption

Total 7D unit placements in the U.S. grew by 66% in the first half of 2025 compared to the prior year, with total revenue commitment of approximately $12 million over the life of the contracts.

Bone Growth Therapies (BGT) Performance

BGT net sales reached $62.6 million, reflecting 6% growth, supported by strong results in both spine and fracture channels.

Positive Free Cash Flow Generation

Orthofix generated positive free cash flow of $4.5 million for the second quarter.

Orthofix (OFIX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

OFIX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.33 / -	-0.71	―	―	―
Jun 30, 2025	2025 (Q2)	-0.49 / -0.36	-0.88	59.09% (+0.52)	―	―
May 06, 2025	2025 (Q1)	-0.55 / -1.35	-0.95	-42.11% (-0.40)
Feb 25, 2025	2024 (Q4)	-0.29 / -0.75	-0.59	-27.12% (-0.16)
Nov 07, 2024	2024 (Q3)	-0.34 / -0.71	0.07	-1114.29% (-0.78)
Aug 06, 2024	2024 (Q2)	-0.36 / -0.88	0.02	-4500.00% (-0.90)
May 07, 2024	2024 (Q1)	-0.51 / -0.95	-0.1	-850.00% (-0.85)
Mar 05, 2024	2023 (Q4)	0.06 / -0.59	0.19	-410.53% (-0.78)
Nov 08, 2023	2023 (Q3)	-0.21 / 0.07	0.13	-46.15% (-0.06)	―
Aug 08, 2023	2023 (Q2)	-0.60 / 0.02	0.08	-75.00% (-0.06)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

OFIX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jun 30, 2025	$11.09	$11.15	+0.54%
May 06, 2025	$13.54	$12.06	-10.93%
Feb 25, 2025	$18.15	$17.51	-3.53%
Nov 07, 2024	$18.40	$18.22	-0.98%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Orthofix International N.V. (OFIX) report earnings?

Orthofix International N.V. (OFIX) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).

What is Orthofix International N.V. (OFIX) earnings time?

Orthofix International N.V. (OFIX) earnings time is at Nov 06, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is OFIX EPS forecast?

OFIX EPS forecast for the fiscal quarter 2025 (Q3) is -0.33.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing